Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simlukafusp alfa - Roche

Drug Profile

Simlukafusp alfa - Roche

Alternative Names: aFAP-IL2v; FAP-IL2v; FAP-IL2v FP; RG 7461; RO 6874281

Latest Information Update: 17 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Fibroblast activation protein antagonists; Immunostimulants; Interleukin-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I Malignant melanoma; Renal cell carcinoma
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 13 Sep 2021 Biomarkers information updated
  • 15 Jun 2021 Roche completes a phase Ib trial in Renal cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Germany, Denmark, France, South Korea, Spain, Canada, Italy and United Kingdom (IV) in June 2021 (NCT03063762)
  • 04 Jun 2021 Efficacy and adverse events data from a phase II trial in Solid tumours presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top